Teva Pharmaceuticals acquires Emalex Biosciences and reports higher first-quarter net income
Updated
Updated · MarketWatch · Apr 29
Teva Pharmaceuticals acquires Emalex Biosciences and reports higher first-quarter net income
3 articles · Updated · MarketWatch · Apr 29
Teva will buy Chicago-based Emalex for $700 million plus up to $200 million in milestone payments, as Q1 net income rose to $369 million.
The Emalex deal, expected to close by Q3, brings a Tourette syndrome drug candidate nearing FDA filing. Teva's Q1 revenue reached $3.98 billion, slightly below analyst estimates.
Teva maintains its 2026 revenue forecast but lowers adjusted earnings guidance to $1.91-$2.11 per share, citing the acquisition's impact. U.S. revenue remained flat as generic sales slipped.
Teva's earnings forecast dropped due to the deal; when will investors see a real financial return?
Is Teva's 'Pivot to Growth' a necessary evolution or a risky gamble on an unproven drug pipeline?
As the Tourette's market grows, can new drugs overcome the high R&D costs and regulatory hurdles?
What are the key FDA approval risks for ecopipam, given the challenges of pediatric drug trials?
How will a novel D1-inhibitor drug change the treatment landscape for Tourette syndrome patients?